The clinical significance of plasma IL-6 levels and other clinicopathologic factors before ICI treatment was evaluated in 106 patients with NSCLC using a Cox proportional hazards regression model (Table 1). This evidence concerns the gene IL6 and non-small cell lung carcinoma.